In Pursuit of Targeted Therapies
Andrew Stainthorpe, PhD
Video Categories: Targeted Therapies
As we learn more about a person’s genetic makeup, the more we are able to target medicines to his/her needs and benefit. With continued research, Dr. Stainthorpe explains, we will be able to identify markers that allow us to target medicines more precisely to get better performance and reduce waste.
Dixie-Lee Esseltine, MD provides a brief overview of the dosing schedule and indications of ixazomib. She also reviews the phase 3 clinical trials of ixazomib that are currently ongoing.
Hal Gerstein, MD, details this neurotransmitter’s role in the development of carcinoid tumors and carcinoid syndrome.